Regeneron Pharmaceuticals (NASDAQ:REGN) Earns “Buy” Rating from Canaccord Genuity Group

Canaccord Genuity Group restated their buy rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note published on Thursday morning, Benzinga reports. Canaccord Genuity Group currently has a $1,152.00 price target on the biopharmaceutical company’s stock.

Several other research analysts also recently issued reports on the stock. Morgan Stanley raised their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an overweight rating in a research report on Wednesday, March 13th. UBS Group raised their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a buy rating in a report on Wednesday, April 17th. Argus upped their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a buy rating in a research note on Tuesday, June 25th. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an outperform rating and a $1,125.00 price objective for the company. Finally, StockNews.com lowered Regeneron Pharmaceuticals from a strong-buy rating to a buy rating in a report on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $1,027.55.

Regeneron Pharmaceuticals Stock Up 0.0 %

Shares of NASDAQ REGN opened at $1,051.03 on Thursday. The business has a 50-day moving average price of $984.27 and a 200 day moving average price of $951.01. The stock has a market cap of $115.81 billion, a PE ratio of 31.05, a price-to-earnings-growth ratio of 2.17 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a 52-week low of $688.52 and a 52-week high of $1,081.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The firm had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Equities research analysts forecast that Regeneron Pharmaceuticals will post 37.23 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the transaction, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,467,684. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Leonard S. Schleifer sold 22,830 shares of the stock in a transaction on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the sale, the chief executive officer now owns 466,877 shares in the company, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 61,971 shares of company stock valued at $61,217,654. Insiders own 7.48% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.0% during the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after buying an additional 91,956 shares in the last quarter. Capital World Investors grew its stake in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after acquiring an additional 23,146 shares during the period. Capital International Investors lifted its stake in shares of Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares during the period. Putnam Investments LLC lifted its stake in shares of Regeneron Pharmaceuticals by 2.1% during the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after purchasing an additional 24,329 shares during the period. Finally, Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $932,571,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.